This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Hologic Beheer
Beheer criteriumcontroles 4/4
De CEO Hologic is Steve MacMillan, benoemd in Dec2013, heeft een ambtstermijn van 12.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 15.93M, bestaande uit 7.9% salaris en 92.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.57% van de aandelen van het bedrijf, ter waarde $ 96.93M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.5 jaar en 7.4 jaar.
Belangrijke informatie
Steve MacMillan
Algemeen directeur
US$15.9m
Totale compensatie
| Percentage CEO-salaris | 7.88% |
| Dienstverband CEO | 12.3yrs |
| Eigendom CEO | 0.6% |
| Management gemiddelde ambtstermijn | 2.5yrs |
| Gemiddelde ambtstermijn bestuur | 7.4yrs |
Recente managementupdates
Recent updates
Narratiefupdate • Apr 10
HOLX: Pending 79 Cash Buyout And Hold Stance Will Guide Near-Term Trading
Analysts now view Hologic’s value as effectively unchanged, with a refreshed price framework still centered around $76.67 per share as they factor in the pending $79 per share cash acquisition and recent downgrades to Hold related to the transaction’s expected early February close. Analyst Commentary Recent research focuses heavily on the pending all cash acquisition at up to $79 per share and how that affects the risk and reward for current shareholders.Narratiefupdate • Mar 26
HOLX: Pending 79 Cash Buyout And Hold Ratings Will Shape Near-Term Outcomes
Analysts now see Hologic's fair value edging to about $76.67 per share, with only minor tweaks to growth, margin and P/E inputs. They are also reflecting increased caution around the pending up to $79 per share cash acquisition by Blackstone and TPG, which has led to a shift in ratings to Hold.Narratiefupdate • Mar 12
HOLX: Pending 79 Cash Buyout And Hold Stance Will Guide Near-Term Outcomes
Analysts have kept their average price target for Hologic broadly unchanged at about $76.60, noting only minor tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions as they factor in the pending $79 per share acquisition by Blackstone and TPG and recent rating changes to Hold. Analyst Commentary Recent research has shifted Hologic to more of a wait and see idea, as the pending buyout at up to $79 per share becomes the main anchor for valuation and expected outcomes.Narratiefupdate • Feb 26
HOLX: Pending 79 Cash Buyout And Hold Rating Will Define Event Path
Analysts have adjusted their price target on Hologic to $79.00 per share, reflecting updated assumptions regarding a future P/E multiple and the pending $79 per share acquisition by funds managed by Blackstone and TPG. Analyst Commentary Recent research updates have shifted toward a more neutral stance on Hologic, with the pending acquisition at $79 per share now the main reference point for valuation rather than long term growth assumptions.Narratiefupdate • Feb 11
HOLX: Buyout Terms And Neutral Ratings Will Shape Event-Driven Returns Through 2026
Analysts have trimmed their fair value estimate for Hologic to US$76.60 from about US$76.92, citing recent downgrades to Hold and Neutral, as the pending US$79 per share buyout by Blackstone and TPG narrows the expected upside. Analyst Commentary Recent research updates around Hologic largely reflect the pending all cash acquisition at US$79 per share, with several firms moving to more neutral stances as the share price tracks closer to the agreed takeout level.Narratiefupdate • Jan 26
HOLX: Buyout Terms And Neutral Ratings Will Frame Returns Through 2026
Narrative Update The analyst fair value estimate for Hologic has edged up by about $0.50 per share as analysts align their targets more closely with the pending private equity acquisition price of up to $79. They are also updating assumptions around the discount rate, modest revenue growth, and future P/E.Narratiefupdate • Jan 12
HOLX: Buyout Deal Terms And Rating Downgrades Will Guide Trading Through 2026
Our updated analyst price target for Hologic edges down slightly to about $76.42 per share. This reflects that analysts now anchor their views more tightly to the proposed Blackstone and TPG takeout value of up to $79 per share and the recent wave of rating downgrades to Neutral or Hold around that deal.Narratiefupdate • Dec 18
HOLX: Buyout Terms And Neutral Ratings Will Shape Trading Through 2026
We trim our Hologic price target slightly to approximately $76.50, as analysts coalesce around the proposed Blackstone and TPG takeout valuation of up to $79.00 per share and see limited upside beyond the agreed acquisition terms. Analyst Commentary Street research following the announced takeout has converged around the proposed valuation, with most firms adjusting ratings and targets to reflect a view that the deal price largely caps near term upside.Narratiefupdate • Dec 04
HOLX: Buyout Deal And Neutral Ratings Will Define Shares Through 2026
The analyst price target for Hologic has inched higher by approximately $0.33 to $76.50, as analysts factor in slightly stronger long term growth and margin assumptions while anchoring valuation to the proposed Blackstone and TPG takeout price near $79 per share. Analyst Commentary Analyst reaction to the proposed Blackstone and TPG acquisition has been mixed, with most firms converging around price targets in the mid to high $70s and resetting ratings to more neutral stances as upside becomes more constrained by the agreed takeout price.Narratiefupdate • Nov 20
HOLX: Acquisition Agreement With Blackstone and TPG Will Shape Stock Outlook Through 2026
Hologic’s analyst price target has increased modestly from $75.08 to $76.17 per share. Analysts view the proposed $79 per share acquisition by Blackstone and TPG as providing a fair valuation and setting a near-term ceiling for the stock.Narratiefupdate • Nov 05
HOLX: Downgrades And Buyout Agreement Will Shift Near-Term Share Performance
Analysts have modestly increased their price target for Hologic from approximately $73.54 to $75.08. They cite the recently announced acquisition by Blackstone and TPG as supportive of current valuation levels, given the company's operating challenges and outlook.Narratiefupdate • Oct 22
Analysts Raise Hologic Targets Amid Strong Results and Positive Acquisition Momentum
Hologic's analyst price target has increased by $1.11, as analysts cite improving financial performance and the impact of the recent acquisition agreement as key factors that support the higher valuation. Analyst Commentary Bullish Takeaways Bullish analysts increased their price targets, pointing to Hologic's improved financial results and raised full-year guidance amid strong recent revenue and EPS performance.Narratiefupdate • Sep 28
Preventive Healthcare And Advanced Diagnostics Will Shape Future Markets
Despite strong quarterly outperformance, higher 2025 guidance, and increased buyout speculation, Hologic's consensus analyst price target was modestly reduced from $73.87 to $72.43 as fiscal 2025 estimates were recalibrated to reflect current demand trends and tariff expectations. Analyst Commentary Strong revenue and EPS outperformance in the recent quarter, with management raising full-year 2025 guidance.Analyseartikel • Sep 13
Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Narratiefupdate • Sep 05
Preventive Healthcare And Advanced Diagnostics Will Shape Future Markets
Despite strong Q3 results, raised FY25 guidance, and increased investor interest from buyout speculation, Hologic’s consensus price target remains unchanged at $73.87 as estimates are now better aligned with actual demand and tariff risks. Analyst Commentary Raised FY25 guidance and Q3 results substantially beat revenue and EPS expectations, demonstrating robust operational performance.Analyseartikel • Aug 04
Analysts Have Made A Financial Statement On Hologic, Inc.'s (NASDAQ:HOLX) Third-Quarter Report
Investors in Hologic, Inc. ( NASDAQ:HOLX ) had a good week, as its shares rose 2.2% to close at US$67.16 following the...Analyseartikel • Jul 19
Is Hologic, Inc. (NASDAQ:HOLX) Trading At A 38% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Hologic fair value estimate is US$103 Hologic is estimated to...Analyseartikel • Jul 01
The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)
With a price-to-earnings (or "P/E") ratio of 26.1x Hologic, Inc. ( NASDAQ:HOLX ) may be sending bearish signals at the...Analyseartikel • Jun 13
Is Hologic (NASDAQ:HOLX) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • May 06
Hologic: Soft Performance, But Cheap Enough
Summary Hologic, Inc.'s appeal has increased due to reduced debt, serial buybacks, and modest valuations, despite recent negative organic growth and pricey acquisitions. The company has shown solid long-term growth, reducing leverage significantly and buying back shares, but recent performance has been soft with flattish sales and earnings. Despite a slight cut in earnings guidance and soft organic growth, Hologic's shares now trade at attractive multiples with very manageable leverage. While cautious due to recent underperformance and expensive acquisitions, I remain upbeat on HOLX stock and plan to add to my long position. Read the full article on Seeking AlphaSeeking Alpha • Jan 17
Hologic: Reasonably, But Not Compellingly Valued
Summary Hologic, Inc. is down approximately 20% from recent highs despite strong quarterly results. The company continues to grow organically and via a series of 'bolt-on' acquisitions. Management also recently added significantly to the company's stock buyback authorization. An updated analysis around Hologic, Inc. follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Oct 28
Hologic: Continued Room Amidst Bolt-On M&A Efforts
Summary Hologic, Inc.'s focus on women's health and strategic M&A, despite pandemic headwinds, positions it for continued growth with a projected $4 billion revenue in 2024. Trading at 20 times earnings, Hologic's quality and growth potential justify its valuation, with shares having risen 10% since May. The company maintains solid organic growth, reducing net debt and executing strategic acquisitions like Endomagnetics and Gynesonics, enhancing its market position. With pandemic-related diagnostics sales declining, Hologic's consistent earnings and strategic moves make it a compelling investment, despite shares not being cheap. Read the full article on Seeking AlphaSeeking Alpha • Aug 27
Hologic Has A Lot Of Fine Qualities, But A Discount Valuation Isn't Among Them
Summary Hologic has been outperforming peers but underperforming the broader medical device sector, with shares up about 5% since my last analysis. Fiscal Q3 results showed consistent beats in Diagnostics, Breast Health, and Surgical segments, but Skeletal Health faced setbacks due to supplier issues. Management has continued to optimize the pandemic-driven surge in Panther placements, with the BV CV/TV panel growing to the second-largest panel in the company's portfolio. Hologic has been a share gainer in molecular diagnostics and is active in M&A, but long-term 5% to 7% revenue growth targets may be too challenging. Long-term revenue growth around 5%, near-term EBITDA margins in the low-30%s, and long-term FCF growth of around 6% support today's valuation and single-digit returns, but Hologic doesn't stand out as undervalued. Read the full article on Seeking AlphaAnalyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Dec 27 2025 | n/a | n/a | US$544m |
| Sep 27 2025 | US$16m | US$1m | US$566m |
| Jun 28 2025 | n/a | n/a | US$557m |
| Mar 29 2025 | n/a | n/a | US$557m |
| Dec 28 2024 | n/a | n/a | US$744m |
| Sep 28 2024 | US$16m | US$1m | US$790m |
| Jun 29 2024 | n/a | n/a | US$702m |
| Mar 30 2024 | n/a | n/a | US$467m |
| Dec 30 2023 | n/a | n/a | US$515m |
| Sep 30 2023 | US$16m | US$1m | US$456m |
| Jul 01 2023 | n/a | n/a | US$484m |
| Apr 01 2023 | n/a | n/a | US$753m |
| Dec 31 2022 | n/a | n/a | US$990m |
| Sep 24 2022 | US$14m | US$1m | US$1b |
| Jun 25 2022 | n/a | n/a | US$2b |
| Mar 26 2022 | n/a | n/a | US$2b |
| Dec 25 2021 | n/a | n/a | US$2b |
| Sep 25 2021 | US$15m | US$1m | US$2b |
| Jun 26 2021 | n/a | n/a | US$2b |
| Mar 27 2021 | n/a | n/a | US$2b |
| Dec 26 2020 | n/a | n/a | US$1b |
| Sep 26 2020 | US$14m | US$1m | US$1b |
| Jun 27 2020 | n/a | n/a | US$497m |
| Mar 28 2020 | n/a | n/a | US$453m |
| Dec 28 2019 | n/a | n/a | US$84m |
| Sep 28 2019 | US$12m | US$1m | -US$204m |
Compensatie versus markt: De totale vergoeding ($USD 15.93M ) Steve } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 14.79M ).
Compensatie versus inkomsten: De vergoeding van Steve is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Steve MacMillan (61 yo)
12.3yrs
Tenure
US$15,931,655
Compensatie
Mr. Stephen P. MacMillan, also known as Steve, serves as a Director of EZ LIFT Rescue Systems, Inc. and Business Leaders for Michigan. He served as an Independent Chairman of the Board at Illumina, Inc. fr...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 12.3yrs | US$15.93m | 0.57% $ 96.9m | |
| Chief Financial Officer | 7.7yrs | US$4.39m | 0.025% $ 4.3m | |
| Chief Operating Officer | 2.3yrs | US$5.08m | 0.0091% $ 1.5m | |
| Group President of International | no data | US$3.46m | 0.050% $ 8.4m | |
| President of Diagnostic Solutions | 3yrs | US$3.13m | 0.0026% $ 440.8k | |
| Chief Information Officer | 4.8yrs | geen gegevens | geen gegevens | |
| Corporate Vice President of Investor Relations | 1.3yrs | geen gegevens | geen gegevens | |
| General Counsel | less than a year | geen gegevens | 0.013% $ 2.1m | |
| Senior Vice President of Global Human Resources | 1.7yrs | geen gegevens | 0.0034% $ 575.9k | |
| VP & Chief of Staff | 12.3yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Global Supply Chain & Regulatory Affairs | 2.5yrs | geen gegevens | geen gegevens | |
| President of GYN Surgical Solutions | 2.3yrs | geen gegevens | 0.0078% $ 1.3m |
2.5yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van HOLX wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 12.3yrs | US$15.93m | 0.57% $ 96.9m | |
| Independent Director | 1.3yrs | US$355.90k | 0.0034% $ 579.3k | |
| Independent Director | 3.3yrs | US$329.97k | 0.00078% $ 131.7k | |
| Independent Director | 7.4yrs | US$329.97k | 0.0042% $ 700.9k | |
| Independent Director | 8.9yrs | US$354.97k | 0.0084% $ 1.4m | |
| Independent Director | 1yr | US$258.46k | 0.00078% $ 131.7k | |
| Independent Director | 14.4yrs | US$329.97k | 0.021% $ 3.6m | |
| Lead Independent Director | 9.3yrs | US$384.97k | 0.0093% $ 1.6m | |
| Independent Director | 2.6yrs | US$344.97k | 0.0019% $ 315.8k |
7.4yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van HOLX wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.4 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/04/06 05:12 |
| Aandelenkoers aan het einde van de dag | 2026/04/06 00:00 |
| Inkomsten | 2025/12/27 |
| Jaarlijkse inkomsten | 2025/09/27 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Hologic, Inc. wordt gevolgd door 25 analisten. 15 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| David Toung | Argus Research Company |
| Charles Butler | Barclays |
| Charley Jones | Barrington Research Associates, Inc. |